DIVI'S LABORATORIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,017 INR | +2.71% |
|
+3.09% | +2.89% |
| Apr. 26 | Weak March Quarter Earnings Weigh Down Indian Equities on Friday | MT |
| Apr. 25 | Divi's Laboratories Plans Up To INR7 Billion Investment to Boost Capacity | MT |
ETFs positioned on Divi's Laboratories Limited
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.68% | 6 M€ | +6.07% | - | |
| 0.20% | 11 M€ | +7.04% | ||
| 0.09% | 19 M€ | +9.85% | ||
| 0.08% | 2,867 M€ | +10.52% | - | |
| 0.08% | 454 M€ | +9.82% | - | |
| 0.08% | 153 M€ | +9.25% | - | |
| 0.07% | 4 M€ | -4.41% | - | |
| 0.06% | 112 M€ | +5.21% | - | |
| 0.03% | 32 M€ | +8.53% | - | |
| 0.03% | 7 M€ | +6.59% | - | |
| 0.02% | 9 M€ | +37.86% | - | |
| 0.01% | 15 M€ | +21.11% | ||
| 0.01% | 45 M€ | 0.00% | - | |
| 0.01% | 34 M€ | +4.68% | - | |
| 0.01% | 34 M€ | +9.50% | - | |
| 0.01% | 391 M€ | +9.24% | - | |
| 0.01% | 14 M€ | -2.76% | ||
| 0.00% | 39 M€ | +6.43% | - | |
| 0.00% | 306 M€ | +6.52% | - |
Divi's Laboratories Limited is specialized in the development and manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients.
Net sales by source of revenue break down into product sales (97.9%) and service sales (2.1%).
At the end of March 2020, the group has 2 production sites located in India.
Sector
Pharmaceuticals
Calendar
2024-05-24
- Q4 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
HOLD
Number of Analysts
25
Last Close Price
3,929
INR
Average target price
3,442
INR
Spread / Average Target
-12.39%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +2.89% | 12.52B | |
| +37.55% | 705B | |
| +32.40% | 583B | |
| -2.94% | 364B | |
| +20.58% | 332B | |
| +5.97% | 291B | |
| +16.21% | 238B | |
| -3.52% | 210B | |
| +10.50% | 209B | |
| +9.46% | 169B |
- Stock Market
- Equities
- DIVISLAB Stock
- Funds and ETFs Divi's Laboratories Limited
